Thinly traded micro cap Genfit (NASDAQ:GNFT) inks a five-year agreement with LabCorp (NYSE:LH) under which the latter will develop a molecular blood test to help identify patients with at-risk nonalcoholic steatohepatitis (NASH). The test, to be commercialized in the U.S. and Canada, will be powered with Genfit's NIS4 non-invasive blood-based diagnostic technology. Financial terms are not disclosed.
In January 2019, Genfit out-licensed NIS4 to LH for use in clinical research through LH subsidiary Covance.
https://seekingalpha.com/news/3617557-genfit-up-47-on-nash-test-deal-labcorp
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.